← Search & browse all drugs
NERVOUS SYSTEM › PSYCHOLEPTICS › HYPNOTICS AND SEDATIVES › Benzodiazepine derivatives
lormetazepam
N05CD06
Forms & Strengths
- Tablets: 0.5 mg, 1 mg, 2 mg
Adult Dosing
- Insomnia: 1 mg to 2 mg orally once daily immediately before bedtime
- Elderly or debilitated patients: 0.5 mg to 1 mg orally once daily to reduce risk of oversedation and ataxia
Pediatric Dosing
- Safety and efficacy in children and adolescents under 18 years have not been established
Indications
- Short-term management of severe or disabling insomnia
Mechanism of Action
- Binds to gamma-aminobutyric acid type A (GABAA) receptors in the central nervous system
- Enhances GABA-mediated chloride ion conductance, resulting in neuronal hyperpolarization, sedation, and anxiolysis
Contraindications
- Hypersensitivity to lormetazepam, other benzodiazepines, or formulation excipients
- Severe hepatic insufficiency
- Severe respiratory insufficiency or sleep apnea syndrome
- Myasthenia gravis
- Acute narrow-angle glaucoma
Adverse Reactions
- Drowsiness, daytime sedation, fatigue, dizziness
- Ataxia, confusion, headache, muscle weakness
- Anterograde amnesia, paradoxical reactions (agitation, aggression)
- Tolerance, physical dependence, and withdrawal syndrome with prolonged use
Drug Interactions
- Central nervous system (CNS) depressants (opioids, antipsychotics, antidepressants, sedative-hypnotics, alcohol) increase risk of profound sedation, respiratory depression, and coma
- CYP3A4 inhibitors may affect metabolism, though lormetazepam undergoes primarily direct glucuronidation via UGT enzymes
Curated Content: Needs Vetting Before Put to Clinical Use